Race appoints Biosynergy to pursue Bisantrene licensing
Filed with ASX · · 3 pages · English
Earlier from Racura Oncology
- September 2018 Quarterly Report
- Appendix 4E & Financial Statements
- June 2018 Quarterly Report
- FDA Grants Bisantrene Rare Paediatric Disease Designation
- Bisantrene poster presented at French Leukaemia Conference
Later from Racura Oncology
- Race signs agreement for Bisantrene NPP in Israel
- Race appoints leading haematologist to support Bisantrene
- Race Receives $228k R&D Tax Incentive Refund
- Principal Investigator appointed for Bisantrene
- Race files Bisantrene IND with FDA
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology